Abstract:
Chimeric antigen receptor (CAR)-engineered T cell therapy for solid tumors is limited by the lack of tumor-restricted and homogeneous expression of tumor antigens 1,2 . Therefore, we engineered an oncolytic virus to express a non-signaling, truncated CD19 (CD19t) protein for tumor-selective delivery, enabling targeting by CD19-specific CAR T cells. Infecting tumor cells with a chimeric oncolytic vaccinia virus coding for CD19t (OV19t) produced de novo CD19 surface-antigen expression prior to virusmediated tumor lysis. Co-cultured CD19-CAR T cells secreted cytokines and elicited potent cytolytic activity against infected tumors. Using multiple mouse tumor models, intratumoral delivery of OV19t induced tumor expression of CD19t and improved tumor control following CD19-CAR T cell administration. CAR T cell-mediated tumor killing also promoted release of virus from dying tumor cells, which propogated tumor expression of CD19t. These data demonstrate a novel immunotherapy approach utilizing oncolytic viruses to promote de novo CAR T cell targeting of solid tumors.
Here, we have exploited the transgene delivery potential of OV to selectively infect and drive tumorspecific expression of a proof-of-concept CAR-targetable tumor antigen, a truncated non-signaling variant of human CD19 (CD19t). We have demonstrated robust CD19t expression on multiple tumor types infected with OV carrying the CD19t gene (OV19t), which promoted activation and tumor killing by CD19-specific CAR T cells. Using human tumor xenograft models as well as an immunocompetent mouse tumor model, we showed potent anti-tumor responses combining OV19t and CD19-CAR T cells.
Importantly, CD19-CAR T cells promoted the early release of intact virus from dying tumor cells, which effectively amplified the combination therapy.
Results:

OV effectively deliver CD19t to solid tumor cells in vitro
For these studies, we utilized a chimeric orthopox OV, designed to infect a large spectrum of tumors 10 , carrying CD19t under the control of the vaccinia synthetic early promoter (PSE) (Fig. 1A) that allows for immediate surface expression of CD19t prior to oncolytic viral-mediated tumor lysis. The hCD19t expression cassette was inserted into the J2R locus encoding thymidine kinase (tk) 10 . This modified OV is termed CF33-(SE)hCD19t, and for the remainder of these studies referred to as OV19t. Of note, the inserted hCD19t gene replacing tk did not significantly impact in vitro infection efficiency or killing activity against human tumor cells ( Fig. S1, A and B ).
To visually assess the ability of the OV to infect and generate surface expression of CD19t on tumor cells, we infected the human triple-negative breast cancer cell line, MDA-MB-468, with OV19t for 16 h at varying multiplicity of infection (MOI), and stained tumor cells to detect expression of intracellular vaccinia virus and cell surface CD19t. We observed intracellular OV19t as well as surface expression of CD19t in an MOI-dependent manner (Fig. 1B) . Interestingly, the intensity of CD19t expression following viral infection appeared higher than with MDA-MB-468 cells that were lentivirally transduced to stably express CD19t under a constitutive EF1α promoter. Expression of CD19t on tumor cells was evaluated at varying MOIs (0.00625 -1) by flow cytometry at 48 h (Fig. 1C ), and further quantified in a timecourse from 24 to 72 h ( Fig. 1D) . Importantly, we observed nearly 100% CD19t expression on tumors cells after 24 h at an MOI 1, and after 72 h at lower MOIs even though 70% of tumor cells remained viable at that timepoint, providing a window of opportunity for targeting by CD19-specific CAR T cells.
Similar trends of infection efficiency, CD19 expression, and OV-mediated killing of tumor cells were observed across multiple tumor types, including Capan-1, DU145, OV90, Panc-1, UM-SCC-1, UM-SCC-47, and U251T cells ( Fig. 1E ).
OV delivery of CD19t to solid tumor cells redirect activity and cytotoxicity of CD19-CAR T cells in vitro
We next assessed whether hCD19t delivered to tumors by OV could activate CD19-CAR T cells. Tumor cells were infected with OV19t at varying MOIs and co-cultured with CD19-CAR T cells at an effector:target (E:T) ratio of 1:2 for 24 h. Cell surface expression of CD25 and 4-1BB (CD137) were used as markers of T cell activation and quantified by flow cytometry. At 24 h, CD19-CAR T cells demonstrated activation against OV19t-infected MDA-MB-468 cells in an MOI-dependent manner (Fig.   S2, A and B ). CD19-CAR T cells were also activated against OV19t-infected MDA-MB-231BR (brainseeking human triple-negative breast cancer) cells after 24 h with similar kinetics as seen with MDA-MB-468 cells (Fig. S3A ). CD19-CAR T cell function was then evaluated by measuring intracellular IFNγ levels and cell-surface CD107a as an early measure of effector activity following 16 h incubation with MDA-MB-468 cells infected with OV19t. CD19-CAR T cells showed robust activity when co-cultured with tumor cells infected with OV19t in an MOI-dependent manner ( Fig. 2A ).
To further quantify the CD19-CAR T cell activity against tumor cells infected by OV19t, supernatants from co-cultures of CD19-CAR T cell and tumor cells with OV19t at varying MOI were collected to evaluate CAR-dependent cytokine production. At 24 h, IFNγ secretion was only observed at an MOI of 1. However, at 48 h, IFNγ secretion was detected in an MOI-dependent manner, reaching levels nearly equivalent to CD19-CAR T cells co-cultured with the positive control, MDA-MB-468 lentivirally transduced to stably express CD19t ( Fig. 2B ). Similar trends were observed with IL-2 secretion at each time point ( Fig. 2C ). To evaluate whether CD19-CAR activity leads to killing of OV19t-infected tumor cells, we performed in vitro tumor killing assays with MDA-MB-468 and U251T and qualitatively evaluated by phase-contrast microscopy in a 72 h time course with OV19t at an MOI of 0.05 (Fig. 2 , D and E). We observed significantly greater killing of tumor cells infected with OV19t and co-cultured with CD19-CAR T cells at all time points when compared with OV19t-infected tumors alone. We further quantified killing ability against MDA-MB-468 cells using flow cytometry. As shown in Fig. 2F , we observed better killing of tumor cells infected with OV19t and co-cultured with CD19-CAR T cells at 24 h. At 48 and 72 h, the lowest MOI of OV19t (0.00625) induced suboptimal virus-mediated lysis of tumor cells (0 -20%), whereas the combination of OV19t with CD19-CAR T cells showed potent tumor killing (60 -70%). Similar combination effects were observed with MDA-MB-231BR cells (Fig. S3B ).
Importantly, we show CAR T cell-selective tumor killing highlighted by a dramatic reduction in CD19tpositive tumor cells in the combination group at all indicated time points and MOIs evaluated ( Fig. 2G ).
Comparable trends in reduction of CD19t-positive tumor cells were observed using U251T, OV90, and UM-SCC-47 cells (Fig. 2H ). We observed no CD19t expression or enhancement in tumor killing by CAR T cells when tumor cells were infected with OV-tk lacking CD19t (Fig. S4, A and B ). Taken together, our data suggest that OV are capable of delivering a de novo tumor antigen, in this case CD19, and inducing antigen-specific CAR T cell-mediated anti-tumor activity.
Anti-tumor efficacy of combination therapy of OV19t and CD19-CAR T cells in human tumor xenograft models
To first evaluate the in vivo anti-tumor activity of OV19t and the dynamics of CD19t expression in infected tumors, we treated mice bearing subcutaneous human MDA-MB-468 triple-negative breast tumors with a single intratumoral (i.t.) injection of OV19t. Choi et al. recently showed significant inhibition of tumor growth following i.t. treatment in MDA-MB-468-bearing nude mice 10 . Therefore, we used varying doses [10 5 , 10 6 , 10 7 plaque forming units (pfu) per mouse] to determine the infection efficiency and CD19t expression in tumors at 3, 7, and 10 d by flow cytometry (Fig. 3A ). We determined that 10 7 pfu of OV19t per mouse was optimal for combination with CD19-CAR T cells on day 10 postinfection in this model, showing approximately 70% of tumor cells expressing CD19t. We then performed an in vivo combination study with i.t. delivery of OV19t at 10 7 pfu per mouse, followed 10 d later by i.t. treatment with 5 x 10 6 of either Mock (untransduced) or CD19-CAR T cells . As expected, MDA-MB-468-bearing mice treated with Mock or CD19-CAR T cells alone showed no anti-tumor activity. Mice treated with OV19t alone or OV19t in combination with Mock T cells slowed tumor growth.
Importantly, the combination of OV19t and CD19-CAR T cells exhibited a marked tumor regression ( Fig. 3 , B and C). We also confirmed the therapeutic benefits of this combination approach using U251T glioblastoma tumor-bearing mice (Fig. 3 , D and E).
Anti-tumor efficacy of combination therapy of OVm19t and CD19-CAR T cells in a murine immunocompetent tumor model
We next evaluated the therapeutic benefits of this combination approach in an immunocompetent mouse tumor model. To that end, we generated OV19t with the murine CD19t gene (OVm19t), and utilized murine splenic T cells to manufacture CD19-CAR T cells. The murine CD19-CAR was generated with a retrovirus containing the anti-mouse CD19 single-chain variable fragment (scFv) antigen-binding domain derived from the 1D3 hybridoma as previously described 11 Taken together, we demonstrate the broad applicability of our combination immunotherapy approach with OV-mediated delivery of CD19t antigen and CD19-CAR T cells using both human xenograft and immunocompetent mouse tumor models.
CD19-CAR T cell-mediated tumor killing promotes the early release of OV19t
One of the potential pitfalls of using OV to deliver CAR T cell target antigens to tumor cells is the suboptimal or non-uniform infection of solid tumors 12, 13 . To address this, we assessed whether CAR T cell-mediated killing of virally-infected tumor cells could enhance the release of oncolytic viral particles for subsequent infection of surrounding tumor cells. Tumor cells were first infected with varying MOI of OV19t and then incubated with Mock or CD19-CAR T cells. Viral titer was then measured in collected supernatants. As shown in Fig. 5A , the combination of OV19t and CD19-CAR T cells demonstrated significant increases in released viral particles, compared with OV19t infection alone or the combination with Mock T cells. We further demonstrated that viral supernatants showed increased infection of fresh tumor cells ( Fig. 5 , B and C), which resulted in significantly greater tumor killing potential (Fig. 5 , D and E) due to increased release of OV when combined with CD19-CAR T cells. The release of oncolytic viral particles from dying tumor cells by antigen-specific CD19-CAR T cells suggests that we may enable more homogeneous infection of tumor cells by this novel combination therapy.
Discussion:
We believe that our findings address a major challenge facing CAR T cell therapies for solid tumors, which include targeting surface proteins that demonstrate heterogeneous expression patterns in tumors, and shared expression of these surface proteins on some normal tissues. We have demonstrated the distinct capability of OV to selectively deliver a CAR-targetable tumor antigen to a human xenograft model of triple-negative breast cancer. Importantly, the combination with CD19-CAR T cells in this model resulted in greater viral spread and the potential for more uniform expression of the CAR target in the tumor. This antigen delivery method may be adopted in other solid cancer types that lack amenable tumor antigens for safe and effective targeting by CAR T cells. CAR T cell therapy and oncolytic virotherapy are complementary modalities for cancer treatment with remarkable potential.
While the introduction of de novo tumor targets distinguishes our approach from other recent studies combining OV with CAR T cells 14, 15 , we plan to further modify these OV to express checkpoint pathway inhibitors, cytokines, and chemokines to augment CAR T cell trafficking and anti-tumor activities.
While we performed these proof-of-concept studies using CD19t as a target, this approach has the potential to introduce other targets, including non-human species-specific antigens 16 , which may also further enhance the anti-tumor efficacy by eliciting host immunity to foreign proteins. However, targeting of CD19 with CAR T cells is a clinically-validated approach for treating hematological malignancies, and has demonstrated clinically-manageable B-cell aplasia 5, 6 , supporting the future clinical development in this potentially safe and effective combination strategy. Also, limited persistence of vaccinia viruses is in part due to antibody-mediated clearance of virus particles 17 , which may be significantly dampened by depleting B cells with CD19-CAR T cells, thus improving systemic and local persistence of OV19t.
Host immunity is important to the outcome of certain OV, as has been shown for HSV 18 . Additionally, T and NK cells have been identified as major components of host immunity after vaccinia infection and contribute to OV-mediated anti-tumor effects 19 . One might envision that following the combination of OV19t and CD19-CAR T cells, new tumor antigens released from dying tumor cells may instigate another wave of anti-tumor immunity mediated by adoptively transferred or endogenous T cells. While we demonstrated robust anti-tumor activity of our combination approach in an immunocompetent mouse tumor model, future studies with this model will not only enable studying the global effects of the OV alone and in combination with CAR T cells, but also enable us to better understand the changes that occur locally in the tumor microenvironment, as well as systemically, following combination therapy. Further, we envision that other oncolytic viruses besides vaccinia (e.g. HSV, Maraba virus, and adenoviruses) can also be exploited in this combination strategy, and that the immunogenic aspects of the therapy may vary depending on the virus.
In summary, we have demonstrated that OV can effectively deliver the CD19-CAR target to solid tumors, which are then susceptible to CD19-CAR T cell-mediated tumor destruction, and further CAR T cell-mediated viral spread (Fig. 5F ). These findings potentially extend the use of clinically-approved CD19-CAR T cells beyond B-cell malignancies and into the treatment paradigm for multiple solid tumors, warranting further investigations of OV19t, or similar viruses delivering CAR targets, in combination with CAR T cells for the treatment of intractable solid tumors. 
Materials and methods:
Cell lines and viruses
Generation of recombinant chimeric orthopoxvirus expressing human and murine truncated CD19 (CD19t)
To generate a shuttle vector containing the human (hCD19t) and murine (mCD19t) CD19t expression cassette with the VACV synthetic early (SE) promoter, the hCD19t and mCD19t cDNAs were PCRamplified from the plasmids hCD19t-2A-IL2-pHIV7 and mCD19t-epHIV7 using Q5 High-Fidelity 2X
Master Mix (New England Biolabs Inc., Ipswich, MA) and the primers: infected/transfected cells were harvested and the recombinant viruses (OV19t) were selected and plaque purified as described previously 21 .
DNA constructs
MDA-MB-468 and MDA-MB-231BR cells were engineered to express human CD19t by transduction with epHIV7 lentivirus carrying the human CD19t gene under the control of the EF1α promoter. A similar procedure was used to engineer MC38 cells to express murine CD19t. The human CD19-28ζ CAR lentiviral construct with truncated human EGFR (EGFRt) separated by a T2A ribosome skip sequence was previously described 22 . The murine CD19-BBζ CAR retroviral construct (pMYs, Cell Biolabs Inc.) contained an anti-mouse CD19-targeted single-chain variable fragment (scFv) sequence derived from the 1D3 hybridoma 11 , a murine CD8 hinge extracellular spacer and transmembrane domain, a murine 4-1BB intracellular costimulatory signaling domain, a murine CD3ζ cytolytic domain, and the human EGFRt separated from the CAR by a T2A ribosome skip sequence.
Human T cell enrichment, lentivirus production and transduction, and ex vivo expansion
T-cell isolation, lentivirus production and transduction, and ex vivo expansion of CAR T cells was performed as previously described 23 .
Murine retrovirus production
Retrovirus was generated by plating PlatE cells for 1 week in complete DMEM with the addition of selection antibiotics including 1 µg/mL puromycin (InvivoGen) and 10 µg/mL blasticidin (InvivoGen).
One day prior to production, cells were washed once and cultured with warm antibiotic-free complete DMEM. On the day of transfection, cells were washed again and 6 µg of plasmid DNA was added with FugeneHD transfection reagent (Promega). Supernatants were collected at 24, 36, and 48 h and frozen at -80°C until further use. 
Murine T cell enrichment, transduction, and ex vivo expansion
Intracellular/extracellular staining and flow cytometry
Flow cytometric analysis was performed as previously described 23 . Tumor cells were identified using Ep-CAM (CD326) (BioLegend, Clone: 9C4). Cell viability was determined using LIVE/DEAD Fixable Violet Dead Cell Stain Kit for 405 nm excitation (Invitrogen). For vaccinia staining, cells were fixed and permeabilized using BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit according to the manufacturer's protocol (BD Biosciences). Cells were then incubated with anti-vaccinia virus primary antibody (Abcam) and incubated for 30 minutes at 4°C in the dark. The cells were washed twice prior to secondary stain with Goat Anti-Rabbit IgG H&L (Alexa Fluor 488) (Abcam) for 30 minutes at 4°C in the dark. The cells were then washed twice prior to resuspension in FACS buffer and acquisition on the MACSQuant Analyzer 10 (Miltenyi Biotec). Data were analyzed with FlowJo software (v10, TreeStar).
OV transduction and T-cell functional assays
For OV transduction and tumor killing assays, CAR T cells and tumor targets were co-cultured at 
Viral Plaque Assay
Following infection of cells with virus as mentioned above, supernatants were collected and processed as previously described 10 . Briefly, tumor cells were plated at 25,000 cells per well and co-cultured with varying MOIs of OV19t and incubated at 37°C for 3 h. Fresh media was added to remove any residual viral particles. Next, the cells were incubated for an additional 4 h, and Mock or CAR T cells were added for 18 h. Supernatants were collected and sonicated three times, and then added to freshly plated tumor cells to evaluate cell killing. 
Immunofluorescence Microscopy
In vivo tumor studies
Statistical analysis
Data are presented as mean ± standard deviation (SD), unless otherwise stated. Statistical comparisons between groups were performed using the unpaired two-tailed Student's t-test to calculate p-value, unless otherwise stated. 
